Tata Steel has lost the bidding battle for Vietnam's Vinausteel and SSE Steel after losing a vote on the resolution for its sale and purchase agreement by Vietnam Industrial Investments, the parent company of the two steel makers.
Five global engineering and power equipment construction majors are in the race to bag the Rs 8,000 crore
Six months after acquiring Anglo-Dutch steel giant Corus, Tata Steel has put the foreign company's aluminium business on the block.
The list, posted on a website link launched by the US regulator, includes ABB, HSBC, Nokia, Unilever, Cadbury, Total and Siemens among others.
The US Food and Drug Administration has tightened rules for selling dietary supplements in the US market, making compliance with current good manufacturing practices mandatory for manufacturers.
Indian drug major Nicholas Piramal India Ltd is likely to be among the first pharmaceutical companies worldwide to develop drugs isolated from the flora and fauna of Antarctica.
Part research being farmed out to medical colleges, universities to cut cost and time.
Srei Infrastructure Finance last month sold 50 per cent stake in a part of its business equipment financing arm to France's largest bank BNP Paribas for Rs 775 crore
Srei Infrastructure Finance is set to be the first Indian company to go for Islamic financing for over Rs 200 crore
These brands belong to about 320 drugs of leading Indian pharmaceutical companies. The Drug Controller General of India's (DCGI's) office feels that these have been launched without its approval.
This is for the second time that Tata Steel is getting into a take-over battle. It acquired the Anglo-Dutch steel company Corus Group after beating rival suitor, CSN of Brazil, through auction.
International brokerages, especially those which have made recent entry into the domestic market, are lining up to acquire the institutional broking business of the city-based Brics Securities.
The 550,000 unorganised drug traders in the country are readying to take on the entry of corporate houses like Anil Dhirubhai Ambani Group
Sources close to the development said the group will shortly take a decision on the business, which has seen interest from large houses like the Tatas and the Ambanis.
close to the development confirmed that a deal could be signed between the parties shortly
RPG Life already has marketing tie-ups with Israel's drug major Teva for the EU market and with the US-based Apotex for the Canadian market.
The average expenditure of pharmaceutical companies on research and development has increased four times in the last five years.
Swiss pharmaceutical major Hoffmann-La Roche's patents rights over Hepatitis C drug Pegasys has been challenged by public interest groups at the Indian Patent Office.
The first off the block appears to be the Reliance Anil Dhirubhai Ambani Group (R-ADAG), which is investing Rs 1,200 crore (Rs 12 billion) in setting up a large drug distribution backbone.
The six-decade-old pharmaceutical company VHB Life Sciences will come out with an initial public offer in July this year to fund its Rs 400-crore
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances